Schedule 13D ownership disclosure

Spero Therapeutics Inc

Security class unavailable · CUSIP: 84833T103

Event date: 2019-10-01

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
1,934,006
Percent of class
10.1000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001387131-20-001836
Form type
SC 13D/A
Filer
GSK plc
CIK
CIK 1131399
Filed
Feb 14, 2020
Reporting period
Oct 01, 2019
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub